DiaMedica Therapeutics Inc. (DMAC)

Market Cap	322.76M +64.8%
Revenue (ttm)	n/a
Net Income	-32.77M
EPS	-0.70
Shares Out	53.88M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	372,554
Open	6.16
Previous Close	6.18
Day's Range	5.71 - 6.16
52-Week Range	3.28 - 10.42
Beta	1.15
Analysts	Strong Buy
Price Target	15.50 (+158.77%)
Earnings Date	May 12, 2026

About DMAC

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 35
• Stock Exchange: NASDAQ
• Ticker Symbol: DMAC
• Website: https://www.diamedica.com

Analyst Summary

According to 4 analysts, the average rating for DMAC stock is "Strong Buy." The 12-month stock price target is $15.5, which is an increase of 158.77% from the latest price.

Price Target

$15.5

(158.77% upside)

Analyst Consensus: Strong Buy